A trial for the drug CT900 (previously called ONX-0801) which targets ovarian cancer cells via a protein called the alpha-folate receptor is being expanded into a larger trial.

The drug could be suitable for women with ovarian cancer for whom chemotherapy has failed, and whose tumours have high levels of the alpha-folate receptor on the surface of cancer cells.

.

Read full article